465 related articles for article (PubMed ID: 1559134)
1. Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate.
Hourani SM; Hall DA; Nieman CJ
Br J Pharmacol; 1992 Feb; 105(2):453-7. PubMed ID: 1559134
[TBL] [Abstract][Full Text] [Related]
2. Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine 5'-diphosphate in human platelets.
Hall DA; Hourani SM
Biochem Pharmacol; 1994 Mar; 47(6):1013-8. PubMed ID: 8147900
[TBL] [Abstract][Full Text] [Related]
3. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors.
Humphries RG; Tomlinson W; Ingall AH; Cage PA; Leff P
Br J Pharmacol; 1994 Nov; 113(3):1057-63. PubMed ID: 7858849
[TBL] [Abstract][Full Text] [Related]
4. Effects of analogues of adenine nucleotides on increases in intracellular calcium mediated by P2T-purinoceptors on human blood platelets.
Hall DA; Hourani SM
Br J Pharmacol; 1993 Mar; 108(3):728-33. PubMed ID: 8467360
[TBL] [Abstract][Full Text] [Related]
5. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
Sanderson HM; Heptinstall S; Vickers J; Lösche W
Blood Coagul Fibrinolysis; 1996 Mar; 7(2):245-8. PubMed ID: 8735830
[TBL] [Abstract][Full Text] [Related]
6. Occupancy of P2 purinoceptors with unique properties modulates the function of human platelets.
Soslau G; Brodsky I; Parker J
Biochim Biophys Acta; 1993 Jun; 1177(2):199-207. PubMed ID: 7684612
[TBL] [Abstract][Full Text] [Related]
7. Aggregation of human and canine platelets: modulation by purine nucleotides.
Soslau G; Arabe L; Parker J; Pelleg A
Thromb Res; 1993 Oct; 72(2):127-37. PubMed ID: 8303650
[TBL] [Abstract][Full Text] [Related]
8. Two different inhibitory effects of pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid on adenosine diphosphate-induced human platelet aggregation.
Windscheif U; Radziwon P; Breddin HK; Bäumert HG; Lambrecht G; Mutschler E
Arzneimittelforschung; 1995 Sep; 45(9):994-7. PubMed ID: 7488321
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo.
Humphries RG; Tomlinson W; Clegg JA; Ingall AH; Kindon ND; Leff P
Br J Pharmacol; 1995 Jul; 115(6):1110-6. PubMed ID: 7582510
[TBL] [Abstract][Full Text] [Related]
10. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
11. Extracellular ATP inhibits agonist-induced mobilization of internal calcium in human platelets.
Soslau G; McKenzie RJ; Brodsky I; Devlin TM
Biochim Biophys Acta; 1995 Jul; 1268(1):73-80. PubMed ID: 7626665
[TBL] [Abstract][Full Text] [Related]
12. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
Shaw LA; Batey AJ; Coker SJ
Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
[TBL] [Abstract][Full Text] [Related]
13. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
14. A possible dual physiological role of extracellular ATP in the modulation of platelet aggregation.
Soslau G; Youngprapakorn D
Biochim Biophys Acta; 1997 Feb; 1355(2):131-40. PubMed ID: 9042333
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.
Hamid-Bloomfield S; Whittle BJ
Br J Pharmacol; 1986 Aug; 88(4):931-6. PubMed ID: 3017497
[TBL] [Abstract][Full Text] [Related]
16. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
17. Effect of phorbol 12-myristate 13-acetate (PMA) on agonist-induced arachidonate release and 5-hydroxytryptamine secretion in human platelets. Dependence of effects on agonist type and time of incubation with PMA.
Krishnamurthi S; Joseph S; Kakkar VV
Biochim Biophys Acta; 1987 Mar; 927(3):429-36. PubMed ID: 3101746
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.
Park HS; Hourani SM
Br J Pharmacol; 1999 Jul; 127(6):1359-66. PubMed ID: 10455285
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR
Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
